Allogene Therapeutics Statistics
Want to see ALLO full AI Analyst Report?
Allogene Therapeutics (ALLO) Stock Statistics & Valuation Metrics
Total Valuation
Allogene Therapeutics has a market cap or net worth of $290.58M. The enterprise value is $337.73M.
- Market Cap
- $290.58M
- Enterprise Value
- $337.73M
Share Statistics
Allogene Therapeutics has 346,467,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 346,467,320
- Owned by Insiders
- 6.58%
- Owned by Institutions
- 55.32%
Financial Efficiency
Allogene Therapeutics’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -52.84%.
- Return on Equity (ROE)
- -0.65
- Return on Assets (ROA)
- -0.46
- Return on Invested Capital (ROIC)
- -52.84%
- Return on Capital Employed (ROCE)
- -0.54
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.26M
- Employee Count
- 151
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Allogene Therapeutics is -1.33. Allogene Therapeutics’s PEG ratio is -0.03.
- PE Ratio
- -1.33
- PS Ratio
- 62.63
- PB Ratio
- 0.74
- Price to FCF
- -2.67
- Price to Operating Cash Flow
- -2.67
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Allogene Therapeutics had revenue of 0 and earned -190.89M in profits. Earnings per share was -0.87.
- Revenue
- 0
- Gross Profit
- -12.36M
- Operating Income
- -206.93M
- Pretax Income
- -190.89M
- Net Income
- -190.89M
- EBITDA
- -177.45M
- Earnings Per Share (EPS)
- -0.87
Cash Flow
In the last 12 months, operating cash flow was -108.63M and capital expenditures -184,000, giving a free cash flow of -108.81M billion.
- Operating Cash Flow
- -108.63M
- Free Cash Flow
- -108.81M
- Free Cash Flow per Share
- -0.31
Dividends & Yields
Allogene Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -37.45%
- Earnings Yield
- -60.10%
Stock Price Statistics
- Beta
- 1.51
- 52-Week Price Change
- -30.17%
- 50-Day Moving Average
- 1.41
- 200-Day Moving Average
- 1.96
- Relative Strength Index (RSI)
- 23.39
- Average Volume (3m)
- 7.40M
Important Dates
Allogene Therapeutics upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Allogene Therapeutics as a current ratio of 7.93, with Debt / Equity ratio of 28.46%
- Current Ratio
- 7.93
- Quick Ratio
- 7.93
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.18
- Interest Coverage Ratio
- -192.50
Taxes
In the past 12 months, Allogene Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Allogene Therapeutics EV to EBITDA ratio is -2.03, with an EV/FCF ratio of -3.03.
- EV to Sales
- 70.98
- EV to EBITDA
- -2.03
- EV to Free Cash Flow
- -3.03
- EV to Operating Cash Flow
- -3.03
Balance Sheet
Allogene Therapeutics has $292.96M in cash and marketable securities with $68.04M in debt, giving a net cash position of $224.92M billion.
- Cash & Marketable Securities
- $292.96M
- Total Debt
- $68.04M
- Net Cash
- $224.92M
- Net Cash Per Share
- $0.65
- Tangible Book Value Per Share
- $1.13
Margins
Gross margin is 100.00%, with operating margin of -4099.33%, and net profit margin of -3759.98%.
- Gross Margin
- 100.00%
- Operating Margin
- -4099.33%
- Pretax Margin
- -3759.98%
- Net Profit Margin
- -3759.98%
- EBITDA Margin
- -3490.75%
- EBIT Margin
- -3731.21%
Analyst Forecast
The average price target for Allogene Therapeutics is $9.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $9.25
- Price Target Upside
- 1003.82% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 36.37%
Scores
- Smart Score
- 7
- AI Score
- 46

